Audio
Teilen
ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The presentations showcase the breadth of Abbott's integrated cancer diagnostics portfolio and demonstrate how its tests support critical decision points—from identifying risk and detecting disease earlier to guiding treatment and monitoring for recurrence.
The data indicate a shift in oncology toward more precise detection, improved personalized care, and clearer treatment decisions without adding patient burden or stress.
"Cancer care is at an inflection point, and diagnostics are playing an increasingly central role in how the disease is detected, treated and managed," said Jake Orville, senior vice president, Abbott's cancer diagnostics business. "By combining tools used for screening, early detection, treatment guidance and recurrence monitoring, we're helping clinicians make more informed decisions at every stage of cancer care, from risk through remission."
Abstract Presentations at ASCO 2026
The Cancerguard® Multi-Cancer Early Detection (MCED) Test
Session times: Monday, June 1, 2026, from 1:30 p.m. to 4:30 p.m. CT
The Oncodetect® Molecular Residual Disease (MRD) Test
Session times: Monday, June 1, 2026, from 1:30 p.m. to 4:30 p.m. CT
The Oncotype DX Breast Recurrence Score® Test
Session times: Monday, June 1, 2026, from 1:30 p.m. to 4:30 p.m. CT
Session time: Monday, June 1, 2026, at 10:51 a.m.
Pipeline Innovation
Session time: Monday, June 1, 2026, from 9:00 a.m. to 12:00 p.m. CT
The Cologuard® Test
Session time: Online Only
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
View original content:https://www.prnewswire.com/news-releases/abbott-showcases-expanding-evidence-across-its-cancer-diagnostics-portfolio-at-asco-2026-302779559.html
SOURCE Abbott
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
